

# UNIVERSAL ADULT HEPATITIS B VACCINATION PLANNER

Use this guide to plan the adoption of HEPLISAV-B and effective implementation of the CDC universal adult hepatitis B vaccination policy in your system<sup>1</sup>

COMMUNICATION	
Who is responsible for creating and distributing communications about the system change to HEPLISAV-B and implementation of the CDC policy?	
How does your system communicate vaccine initiatives? Who will initiate communication?	
When will the initial communication be sent? How often will there be follow-up communications?	
EDUCATION	
What education will be provided to system employees (HEPLISAV-B, the effective implementation of the CDC policy, how to identify and vaccinate eligible patients, etc)?	
Who will lead educational efforts with system employees?	
How can Dynavax support educational efforts within your system (in-services, virtual meetings, HEPLISAV-B educational materials)?	

## INDICATION

HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.

## IMPORTANT SAFETY INFORMATION

Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.

Please see additional Important Safety Information on the next page, and scan the QR code or ask your representative for full [Prescribing Information](#).

**HEPLISAV-B**<sup>®</sup>  
Hepatitis B Vaccine (Recombinant), Adjuvanted  
**2 DOSES. 1 MONTH. DONE.<sup>2</sup>**

## EVALUATION

What are some of your system's goals in the adoption of HEPLISAV-B and effective implementation of the CDC policy?	
How will you measure overall effectiveness?	
How can your system address noncompliance with adopting HEPLISAV-B and the CDC policy?	

### IMPORTANT SAFETY INFORMATION (continued)

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B.

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B.

Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.

**References:** 1. Centers for Disease Control and Prevention. Recommended adult immunization schedule for ages 19 years or older, United States, 2022. Accessed January 3, 2023. <https://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf> 2. HEPLISAV-B. Package insert. Dynavax Technologies Corporation; 2020.

The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%).

To report suspected adverse reactions, contact 1-84-HEPLISAV (1-844-375-4728) or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).



Please scan the QR code or ask your representative for full [Prescribing Information](#).